A 28-year-old man with hyperthyroidism is being evaluated for antithyroid drug choice. Which is the most common reason for switching from methimazole to propylthiouracil (PTU) in clinical practice?

Explanation

## Most Common Reason for Switching to PTU **Key Point:** Pregnancy, particularly in the first trimester, is the most common clinical reason to switch from methimazole to PTU. Methimazole is associated with methimazole embryopathy (rare but serious), while PTU has a better safety profile in early pregnancy. ### Comparison of Methimazole vs PTU in Pregnancy | Feature | Methimazole | PTU | |---|---|---| | Methimazole embryopathy | Yes (rare: 0.1–0.3%) | No | | Placental transfer | Moderate | High (but safer in 1st trimester) | | Protein binding | Low | High (~80%) | | Preferred trimester | 2nd and 3rd | 1st trimester | | Agranulocytosis risk | 0.2–0.5% | 0.1–0.5% | | Hepatotoxicity | Rare | More common (0.1–1%) | **High-Yield:** The standard obstetric practice is to use PTU in the first trimester (when organogenesis occurs) and then switch to methimazole in the 2nd and 3rd trimesters (better safety profile and less frequent dosing). This is the most common clinical scenario for switching. **Clinical Pearl:** Methimazole embryopathy includes: - Methimazole-induced cutis aplasia (scalp defects) - Choanal/esophageal atresia - Developmental delay While rare, these are serious enough to avoid methimazole in the first trimester. ### Why PTU in First Trimester? 1. High protein binding → less placental transfer of active drug 2. No known embryopathy 3. Blocks peripheral conversion of T₄ to T₃ (additional benefit) 4. Pregnancy is the single most common reason for drug switching in clinical practice **Mnemonic:** **PMM** = **P**regnancy → **M**ethimazole risk → **P**TU switch